Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Industry

7 Feb 2023

Awakn Life Sciences Granted Fast-Track Designation from UK for Ketamine Therapy

Awakn Life Sciences continues to advance its primary program forward, receiving fast-track innovation approval from UK regulators....

By Jason Najum

Industry

1 Feb 2023

Apex Labs Granted Approval for At-Home Phase 2b Psilocybin Trial

Lesser-known psychedelic firm Apex Labs has announced approval by Health Canada of a Phase 2b trial....

By Jason Najum

Law & Politics

13 Jan 2023

2023 Starts With Psychedelic Decrim Measures In Several States

2023 has started with several states introducing psychedelic decriminalization measures....

By Jason Najum

Industry

10 Jan 2023

A Deeper Look at atai Life Sciences’ Company Update

atai Life Science has released its most recent corporate update....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

30 Dec 2022

2022 End-of-Year Review: MindMed

Continuing our series of 2022 end-of-year reviews, we take a look at MindMed’s last 12 months....

By Jason Najum

Industry

23 Dec 2022

2022 End of Year Review: atai Life Sciences

We take a brief look atai Life Sciences and what they’ve accomplished in 2022...

By Jason Najum

Finance

16 Dec 2022

Gilgamesh Pharmaceuticals Raises $39 Million in Series B Financing

Gilgamesh Pharmaceuticals has announced the closing of a $39 million Series B financing....

By Jason Najum

Law & Politics

15 Dec 2022

Breaking News: Quebec First Province to Cover Costs of Psilocybin Therapy

In this Canadian-first, treatment for psychedelic therapy has been covered by the government health care system....

By Jason Najum

Industry

13 Dec 2022

Awakn’s Phase 3 Trial Launching With UK National Health Service

Awakn Life Sciences has announced that its Phase 3 trial using ketamine for Alcohol Use Disorder is going ahead in several sites across the UK....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.